Octarine Bio, the synthetic biology drug development company that produces psilocybin from sugar using fermentation, partners with clinical research organisation Clerkenwell Health to deliver clinical trials. – Europe’s commercial psychedelic healthcare ecosystem is growing, building on a strong heritage of academic and civil society support – A partnership between these two innovative startups…


Previous articleDelix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
Next articleMindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin